Induction of a Systemic Immune Response by a Polyvalent Melanoma-Associated Antigen DNA Vaccine for Prevention and Treatment of Malignant Melanoma
Open Access
- 1 March 2002
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 5 (3) , 291-299
- https://doi.org/10.1006/mthe.2002.0537
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- In Vivo Activation of Antigen-Specific CD4 T CellsAnnual Review of Immunology, 2001
- Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-γ retroviral vector in melanoma patientsCancer Gene Therapy, 2000
- Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protectionGene Therapy, 2000
- Immunogene Therapy for Murine Melanoma Using Recombinant Adenoviral Vectors Expressing Melanoma-Associated AntigensMolecular Therapy, 2000
- Protective immunization against melanoma by gp100 DNA–HVJ-liposome vaccineGene Therapy, 1999
- The expanding universe of T-cell subsets: Th1, Th2 and morePublished by Elsevier ,1999
- Antibody Responses to Melanoma/Melanocyte Autoantigens in Melanoma PatientsJournal of Investigative Dermatology, 1998
- INDUCTION OF TH1 AND TH2 CD4+T CELL RESPONSES:The Alternative ApproachesAnnual Review of Immunology, 1997
- Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma VaccineAnnals of Surgery, 1992
- Establishment of Stable, Cell-Mediated Immunity that Makes "Susceptible" Mice Resistant to Leishmania majorScience, 1992